Abstract
Introduction
Mosaic Variegated Aneuploidy Syndrome 2 (MVA2) is a rare genetic disorder characterized by a variable percentage (25–50%) of constitutional mosaic aneuploidies. To our knowledge, only 15 cases worldwide with only 1 Indian family and six pathogenic variants of MVA2 have been described.
Clinical features
We now report a 2nd Indian family with two female siblings who presented with short stature, dysmorphism, microcephaly, and a history of consanguinity.
Diagnosis and intervention
Karyotyping was reported to be normal (46, XX) in both siblings. Whole exome and Sanger sequencing revealed a homozygous c.1388_1391del(p.Lys463IlefsTer3) in exon 11 in the CEP57 gene (NM_014679.5), a novel variant that leads to the termination of protein translation causing MVA2. Testing of a phenotypically typical sibling showed a heterozygous status for the identified variant.
Conclusion
This report highlights an important lesson for genetic testing. Our findings enrich the CEP57 mutational spectrum and emphasize the importance of genetic testing and karyotyping in patients with microcephaly and short stature.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
Short stature is a common condition affecting children due to genetic, epigenetic, and environmental factors. Advancements in genetic analysis have enabled the identification of new genetic causes, shedding light on the molecular mechanisms behind growth failure [1]. Mosaic variegated aneuploidy syndrome type 2(MVA2) is a rare autosomal recessive disorder characterized by chromosome gains and losses called constitutional aneuploidy in different chromosomes and tissues, especially trisomies, double trisomies, and monosomies [2]. MVA2 is due to defective cell division, causing disjunction of chromosomes during mitosis [3]. The clinical manifestations of MVA2 include intrauterine growth restriction, microcephaly, facial anomalies, and intellectual disability. Although mosaic aneuploidies should be observed on karyotype, they may be dismissed as an artifact. Only 15 cases with only 1 Indian family with MVA2 have been reported in the literature. We report another Indian family with two siblings with novel homozygous pathogenic variants in the CEP57 gene causing MVA2 (MIM#614114).
2 Clinical case report description
An Indian family engaged in third-degree consanguineous marriage brought their two affected children (referred to as F1 and F2) for evaluation of short stature. These were the first two girl siblings among the four children. Their parents were second cousins, and the family history (including the other two children) was unremarkable, as shown in Fig. 1 (Pedigree). They were enrolled in the study after taking written informed consent.
The proband(F1), a 13-year-old Indian female, who her parents brought to the OPD with complaints of inability to gain height, is the first child, born via normal vaginal delivery at 37 weeks, with a birth weight of 1500 g (−2.14 SD) requiring neonatal intensive care unit admission for low birth weight. She had achieved milestones typically according to her parents but had poor academic performance with an intelligence quotient (IQ) of 70% and a mental age of 11 years, indicating mild intellectual disability. Growth retardation was observed after 5 years of age. On examination, her anthropometry revealed a height of 108 cm (− 6.27 SD), a weight of 16.5 kg (− 4.47 SD), and a head circumference of 49 cm (<− 3 SD). She had dysmorphisms like triangular face, telecanthus, low set ears, brachydactyly, clinodactyly, and overlapping 4th and 5th toe (Fig 2). Written consent was obtained to publish the images. Sexual maturity rating (SMR) showed pre-adolescent growth stage and cafe-au-lait spots over the vulva. The bone age was 14 years, and an abdominal ultrasound showed a small uterus with multiple small follicles in the ovaries. 2D Echo was normal. Brain MRI revealed a small pituitary gland.
The younger sister (F2) of the proband was 11 years old. Her birth history was unremarkable. She exhibited microcephaly, facial dysmorphism, and low-set ears, consistent with her sister’s presentation. She had a history of recurrent respiratory infections. Her IQ revealed mild intellectual disability (68%) and a mental age of 8 years. On examination, her anthropometry revealed a height of 108 cm (<− 3SD), a weight of 15 kg (<− 3SD), and a head circumference of 47 cm (<− 3 SD). SMR showed pre-adolescent Stage. MRI of the Brain revealed a hypoplastic anterior pituitary similar to that of F1. The bone age was 10–12 years, and pelvic ultrasound showed normal findings. The mid-parental height was 158 cm. And the rest of the family members were healthy.
Short stature was evaluated as per the guidelines. Level 1 laboratory investigations like CBC, Liver and renal function tests, venous blood gas, and stool routine microscopy were all within normal limits for both affected siblings. Endocrinological evaluation for short stature revealed normal thyroid hormone levels, normal growth hormone, and cortisol levels. Karyotyping was performed in F1 and F2 by GTG Banding using a peripheral blood sample. 20 cells were analyzed, and five cells were karyotyped using ISCN-2020, revealing a normal female karyotype (46, XX). Although mosaic aneuploidies should be observed on karyotype, they were dismissed as an artifact in the report. Whole Exome Sequencing (WES) revealed autosomal recessive Mosaic Variegated Aneuploidy Syndrome Type 2 with homozygous CEP57 variant. WES revealed a c.1388_1391del (p.Lys463IlefsTer3) in exon 11 in the CEP57 gene (NM_014679.5) chromosome coordinates chr11:95831137-95831140 (GRCh38.p14)). This mutation could not be found in genomAD and ClinVar databases. Still, it is classified as likely pathogenic according to the guidelines recommended by the American College of Medical Genetics and Genomics (ACMG). Sanger sequencing was performed in the proband, affected sibling, and the typical sibling and confirmed the homozygous variant in the F1 and F2 (Fig 3).
The proband was treated with Growth hormone in a local hospital for 1 year at the age of 13 years. The drug dose was 0.15–0.17 U kg−1 d−1. The patient was followed up after 20 months. Anthropometric examination revealed an insignificant change in height.
3 Discussion
Herein, we have discussed the clinical details of two Indian siblings with MVA2 and compared details of 15 more reported individuals (1 report each of Indian origin, Pakistani, Chinese and 2 Caucasian origin, 2 of Mexican, 4 of Moroccan ethnicity); a total of 17 patients with MVA2 [3,4,5,6,7,8,9,10,11,12] (Supplementary Table 1). We have discussed these patients’ phenotypic and molecular characteristics according to various ethnic backgrounds. According to our data, most of the molecular analyses reported homozygosity (15/17) given the autosomal recessive inheritance pattern, and 2/17 were compound heterozygous in inheritance. All reported variants were distributed in Exons 5,9,3,11, and Intron 3.
It is observed that individuals of Moroccan ethnicity are detected with a common variant, i.e., c.915_925dup, making it the most common variant detected so far in the literature.
Marked growth retardation is observed in all cases of prenatal origin 15/17(88%), which is a hallmark of this condition [4].
In 13/17 (76.5%) of these cases, various skeletal manifestations have been reported, including rhizomelic shortening of upper and lower extremities, brachydactyly, thumb hypoplasia, and osteolytic lesions in the skull [4]. Our siblings also had similar bony abnormalities. Research conducted by Aziz et al. on the mouse models mimicking the MVA Disease mutation found that the CEP57 protein regulates Fibroblast growth factor 2 (FGF2), a key molecule in bone formation. FGF2 has been shown to stimulate bone formation and is expressed in osteoblastic cells [7]. FGF2 has an established role as a binding partner of CEP57 involved in FGF2 nuclear translocation. This mechanism could explain the observed skeletal abnormalities in MVA2 individuals [4, 7]. Of the data available for facial dysmorphisms, nearly all patients 13/14 (92.8%) had dysmorphisms. Data was unavailable in 2 studies. Sparse hair was also seen in other cases, including our proband. However, the presence of microcephaly wasn’t a constant finding, seen in 10/17(58.8%) cases only [4]. Cognitive development was reported to be normal in 4(25%) cases, while both our cases had mild intellectual disability.
MRI brain was reported to be abnormal in 8/15(53.3%) cases. Individuals with missing data are not taken accountable. Our cases had pituitary atrophy in one sibling and hypoplasia in the other, which was similar to the other reported cases [6]. Additional phenotypic features in this report include the presence of a small uterus and multiple small follicles in the ovary on abdominal ultrasound and a cafe au lait spot over the vulva in our proband. It is important to note that these are just initial observations, and further studies are needed to confirm and expand upon these findings. However, incorporating these additional features into the discussion provides a more comprehensive understanding of the diverse phenotypic manifestations associated with MVA2.
Mosaic aneuploidies on chromosome metaphases are a universal hallmark of MVA syndrome. The karyotype was reported as normal in several cases like ours. Our patients had homozygous c.1388_1391del (p.Lys463IlefsTer3) mutation described first in the literature.
MVA2 is an ultra-rare single-gene disease with prenatal or post-natal onset growth failure with typical dysmorphic features of triangular face, relative macrocephaly, and short limbs. These two cases highlight the importance of genetic testing, especially in cases of short stature with no reported aneuploidies on karyotyping. Appropriate genetic testing is paramount in short-stature cases as it aids in accurate diagnosis, identification of specific genetic disorders, treatment, and decision-making, and facilitates familial and reproductive counseling.
Data availability
The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.
Code availability
Not applicable.
References
Li Q, Chen Z, Wang J, Xu K, Fan X, Gong C, Wu Z, Zhang TJ, Wu N. Molecular diagnostic yield of exome sequencing and chromosomal microarray in short stature: a systematic review and meta-analysis. JAMA pediatrics. 2023 Nov 1
Lane AH, Aijaz N, Galvin-Parton P, Lanman J, Mangano R, Wilson TA. Mosaic variegated aneuploidy with growth hormone deficiency and congenital heart defects. Am J Med Genet. 2002;110(3):273–7.
Snape K, Hanks S, Ruark E, Barros-Núñez P, Elliott A, Murray A, Lane AH, Shannon N, Callier P, Chitayat D, Clayton-Smith J. Mutations in CEP57 cause Mosaic variegated aneuploidy syndrome. Nat Genet. 2011;43(6):527–9.
Santos-Simarro F, Pacio M, Cueto-González AM, Mansilla E, Valenzuela-Palafoll MI, López-Grondona F, Lledín MD, Schuffelmann C, Del Pozo Á, Solis M, Vallcorba P. Mosaic variegated aneuploidy syndrome 2 caused by biallelic variants in CEP57, two new cases and review of the phenotype. Eur J Med Genet. 2021;64(11):104338.
Langeh N, Saluja S, Ethayathulla AS, Jana M, Shukla R, Palanichamy JK, Gupta N. Mosaic variegated aneuploidy syndrome 2 with biallelic novel CEP57 splice site variation in Indian siblings: expanding the clinical and molecular spectrum. Clin Genet. 2023;103(4):478–83.
Dery T, Chatron N, Alqahtani A, Pugeat M, Till M, Edery P, Sanlaville D, Schluth-Bolard C, Nicolino M, Lesca G, Putoux A. Follow-up of two adult brothers with homozygous CEP57 pathogenic variants expands the phenotype of Mosaic Variegated Aneuploidy Syndrome. Eur J Med Genet. 2020;63(11):104044.
Aziz K, Sieben CJ, Jeganathan KB, Hamada M, Davies BA, Velasco RO, Rahman N, Katzmann DJ, Van Deursen JM. Mosaic-variegated aneuploidy syndrome mutation or haploinsufficiency in Cep57 impairs tumor suppression. J Clin Investig. 2018;128(8):3517–34.
Pinson L, Mannini L, Willems M, Cucco F, Sirvent N, Frebourg T, Quarantotti V, Collet C, Schneider A, Sarda P, Genevieve D. CEP57 mutation in a girl with mosaic variegated aneuploidy syndrome. Am J Med Genet A. 2014;164(1):177–81.
Pezzani L, et al. Double homozygosity in CEP57 and DYNC2H1 genes detected by WES: composite or expanded phenotype? Mol Genet Genom Med. 2020;8: e1064.
De la Torre-García O, Mar-Aldama R, et al. A homozygous CEP57 c 915_925dupCAATGTTCAGC mutation in a patient with mosaic variegated aneuploidy syndrome with rhizomelic shortening in the upper and lower limbs and a narrow thorax. Eur J Med Genet. 2019;62(3):195–7.
Feng B, Chang G, Zhang Q, Li X, Tang Y, Gu S, Wang Y, Wang J, Wang X. A novel CEP57 variant associated with mosaic variegated aneuploidy syndrome in a Chinese female presenting with short stature, microcephaly, brachydactyly, and small teeth. Mol Genet Genom Med. 2022;10(6): e1951.
Brightman DS, Ejaz S, Dauber A. Mosaic variegated aneuploidy syndrome caused by a CEP57 mutation diagnosed by whole exome sequencing. Clinic Case Rep. 2018;6:1531–4.
Funding
No funding was received to assist with preparing this manuscript. No funding was received to conduct this study.
Author information
Authors and Affiliations
Contributions
S.M. and Su.M. performed the clinical evaluation and recruited the family. Su.M. advised regarding genetic testing. S.M. and P.K. did the initial draft and edited the manuscript. P.M.K supervised report and critical revision of article. All authors proofread the final manuscript. All authors have participated sufficiently in the work to take public responsibility for appropriate portions of the content and agreed to be accountable for all aspects of the work in ensuring that questions related to its accuracy or integrity.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Ethical clearance was given by the Institutional Ethics Committee(IEC-GMCA) Chh. Sambhajinagar that follows procedures which are in compliance with the requirements with ICH(International Corporation of Harmonization) guidance related to GCP(Good Clinical Practice). The patient party has provided written informed consent for the publication of data in this study.
Competing interests
The authors have no competing interests to declare that are relevant to the content of this article.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Mundada, S., Magar, S., Kalai, P. et al. A case report of Indian siblings with short stature due to novel variant in the CEP57 gene, causing Mosaic Variegated Aneuploidy Syndrome Type 2 and review of the phenotype of related patients. Discov Med 1, 50 (2024). https://doi.org/10.1007/s44337-024-00057-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s44337-024-00057-z